Related Experiment Video
Updated: Aug 12, 2026
Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery
Published on: August 22, 2016
A Mg-Al layered double hydroxide-based nanocomposite functionalized with PTHrP-2 and loaded with polyoxometalates for
Luhao Li1, Guang Shi1, Chen Chai2
1Department of Orthopedics, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
Abstract:
Osteoarthritis (OA) is a chronic degenerative joint disease characterized by cartilage degeneration, inflammation, and oxidative stress. Existing monotherapies exhibit limited efficacy as they fail to comprehensively address the disease's complex pathological features. This study developed a multifunctional nanocomposite (LDH-P@P2) based on magnesium-aluminum layered double hydroxide (LDH) loaded with a molybdenum-based polyoxometalate (POM) and the parathyroid hormone-related peptide-2 (PTHrP-2) for OA treatment. The nanocomposite functions as a pH-responsive carrier that degrades within the acidic microenvironment of OA lesions, enabling the controlled release of magnesium ions (Mg2+), POM, and PTHrP-2. This system delivers multi-pathway synergistic therapeutic effects including reactive oxygen species (ROS) scavenging, promotion of chondrocyte proliferation, inhibition of apoptosis, immunomodulation via macrophage polarization, regulation of osteogenic differentiation, and amelioration of the acidic microenvironment. Transcriptome sequencing revealed that the therapeutic mechanism primarily involves activation of the PI3K/Akt pathway and inhibition of the MAPK pathway. In vivo experiments confirmed that intra-articular injection of LDH-P@P2 significantly alleviated OA progression in an anterior cruciate ligament transection (ACLT) rat model, reducing joint effusion and osteophyte formation while promoting cartilage matrix synthesis, improving subchondral bone structure, and demonstrating good biocompatibility. This work proposes a novel therapeutic strategy for OA that integrates multi-pathway synergy with pH-responsive targeting.
Insights
A novel nanocomposite effectively treats osteoarthritis (OA) by releasing multiple therapeutic agents in acidic joint environments. This multi-pathway approach targets inflammation and cartilage degeneration, offering a promising new strategy for OA therapy.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Rheumatology
Background:
- Osteoarthritis (OA) is a degenerative joint disease with complex pathology, including cartilage degradation, inflammation, and oxidative stress.
- Current monotherapies for OA show limited effectiveness due to their inability to address these multifaceted pathological features comprehensively.
Purpose of the Study:
- To develop a multifunctional nanocomposite, LDH-P@P2, for enhanced osteoarthritis treatment.
- To leverage a pH-responsive delivery system for controlled release of therapeutic agents within the acidic OA microenvironment.
Main Methods:
- Fabrication of a magnesium-aluminum layered double hydroxide (LDH) nanocomposite loaded with a molybdenum-based polyoxometalate (POM) and parathyroid hormone-related peptide-2 (PTHrP-2).
- Utilized transcriptome sequencing to elucidate the underlying therapeutic mechanisms, focusing on key signaling pathways.
- Conducted in vivo studies using an anterior cruciate ligament transection (ACLT) rat model to evaluate therapeutic efficacy and biocompatibility.
Main Results:
- The LDH-P@P2 nanocomposite demonstrated pH-responsive degradation, releasing Mg2+, POM, and PTHrP-2 to scavenge reactive oxygen species (ROS), promote chondrocyte proliferation, inhibit apoptosis, modulate macrophage polarization, and regulate osteogenic differentiation.
- Transcriptome analysis indicated that the therapeutic effects are mediated by the activation of the PI3K/Akt pathway and inhibition of the MAPK pathway.
- In vivo experiments showed significant alleviation of OA progression, reduced joint effusion and osteophyte formation, enhanced cartilage matrix synthesis, and improved subchondral bone structure with good biocompatibility.
Conclusions:
- The developed multifunctional nanocomposite, LDH-P@P2, offers a synergistic therapeutic strategy for osteoarthritis by combining multi-pathway effects with pH-responsive targeting.
- This innovative approach effectively targets the complex pathological features of OA, presenting a promising new therapeutic avenue.
